Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Shree Ganesh Remedies reported Q4FY26 revenue of Rs 33.20 crore, up 36% YoY, driven by strong pharma intermediates and specialty chemicals sales. However, full year FY26 revenue grew only 1% to Rs 109.29 crore, indicating weak growth momentum throughout the year. PAT declined 23% YoY to Rs 17.77 crore for FY26, while EBITDA fell 11% to Rs 35.02 crore. EBITDA margins compressed significantly by 406 bps to 32.0% for FY26. The company cited challenging operating conditions including European market slowdown, geopolitical uncertainty, raw material volatility, and customer deferrals. Promoter highlighted successful completion of pilot trials for CRAMS projects and confirmed Block 7 expansion remains on track for Q2FY27 commercial production, positioning the company for future growth.
The stock may face near-term pressure due to declining profitability and compressed margins despite flat revenue growth. However, successful CRAMS project transitions and upcoming capacity expansion from Q2FY27 could provide future upside potential. Export revenue (Rs 63.10 crore) remains a key growth driver representing 58% of total FY26 revenue.